原标题:康方生物-B新药进展 来源:每日经济新闻每经AI快讯,康方生物-B董事会宣布,公司在第35届肿瘤免疫治疗学会年会(SITC 2020)上公布了自主研发的下一代靶向CD47的人源化单克隆抗体(研发代号: AK117)的首次人体临床研究进展,标题为《一项评估下一代抗CD47单抗(AK117) 用于治疗复发╱难治性的晚期或转移性实体瘤或淋巴瘤患者的安全性、药代动力学和抗肿瘤活性的I期临床研究》。...
Source Link原标题:康方生物-B新药进展 来源:每日经济新闻每经AI快讯,康方生物-B董事会宣布,公司在第35届肿瘤免疫治疗学会年会(SITC 2020)上公布了自主研发的下一代靶向CD47的人源化单克隆抗体(研发代号: AK117)的首次人体临床研究进展,标题为《一项评估下一代抗CD47单抗(AK117) 用于治疗复发╱难治性的晚期或转移性实体瘤或淋巴瘤患者的安全性、药代动力学和抗肿瘤活性的I期临床研究》。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.